-DOCSTART- -X- O
Lassa -X- _ B-Patient
fever -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
LASV -X- _ I-Patient
) -X- _ I-Patient
causes -X- _ O
acute -X- _ O
viral -X- _ O
haemorrhagic -X- _ O
fever -X- _ O
with -X- _ O
symptoms -X- _ O
similar -X- _ O
to -X- _ O
those -X- _ O
seen -X- _ O
with -X- _ O
Ebola -X- _ O
virus -X- _ O
infections. -X- _ O
LASV -X- _ O
is -X- _ O
endemic -X- _ O
to -X- _ O
West -X- _ O
Africa -X- _ O
and -X- _ O
is -X- _ O
transmitted -X- _ O
through -X- _ O
contact -X- _ O
with -X- _ O
excretions -X- _ O
of -X- _ O
infected -X- _ O
Mastomys -X- _ B-Patient
natalensis -X- _ I-Patient
rodents -X- _ I-Patient
and -X- _ O
other -X- _ O
rodent -X- _ O
species. -X- _ O
Due -X- _ O
to -X- _ O
a -X- _ O
high -X- _ O
fatality -X- _ O
rate -X- _ O
, -X- _ O
lack -X- _ O
of -X- _ O
treatment -X- _ O
options -X- _ O
and -X- _ O
difficulties -X- _ O
with -X- _ O
prevention -X- _ O
and -X- _ O
control -X- _ O
, -X- _ O
LASV -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
high-priority -X- _ O
pathogens -X- _ O
included -X- _ O
in -X- _ O
the -X- _ O
WHO -X- _ O
R -X- _ O
& -X- _ O
D -X- _ O
Blueprint. -X- _ O
The -X- _ O
WHO -X- _ O
LASV -X- _ O
vaccine -X- _ O
strategy -X- _ O
relies -X- _ O
on -X- _ O
availability -X- _ O
of -X- _ O
effective -X- _ O
diagnostic -X- _ O
tests. -X- _ O
Current -X- _ O
diagnostics -X- _ O
for -X- _ O
LASV -X- _ O
include -X- _ O
in-house -X- _ B-Intervention
and -X- _ I-Intervention
commercial -X- _ I-Intervention
( -X- _ I-Intervention
primarily -X- _ I-Intervention
research-only -X- _ I-Intervention
) -X- _ I-Intervention
laboratory-based -X- _ I-Intervention
serological -X- _ I-Intervention
and -X- _ I-Intervention
nucleic -X- _ I-Intervention
acid -X- _ I-Intervention
amplification -X- _ I-Intervention
tests. -X- _ I-Intervention
There -X- _ O
are -X- _ O
two -X- _ O
commercially -X- _ O
available -X- _ O
( -X- _ O
for -X- _ O
research -X- _ O
use -X- _ O
only -X- _ O
) -X- _ O
rapid -X- _ O
diagnostic -X- _ O
tests -X- _ O
( -X- _ O
RDTs -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
multiplex -X- _ O
panels -X- _ O
for -X- _ O
differential -X- _ O
detection -X- _ O
of -X- _ O
LASV -X- _ O
infection -X- _ O
from -X- _ O
other -X- _ O
endemic -X- _ O
diseases -X- _ O
with -X- _ O
similar -X- _ O
symptoms -X- _ O
have -X- _ O
been -X- _ O
evaluated. -X- _ O
However -X- _ O
, -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
diagnostic -X- _ O
gaps -X- _ O
remain. -X- _ O
Lineage -X- _ B-Outcome
detection -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
challenge -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
genomic -X- _ I-Outcome
diversity -X- _ I-Outcome
of -X- _ I-Outcome
LASV -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
pan-lineage -X- _ I-Outcome
sensitivity -X- _ I-Outcome
for -X- _ I-Outcome
both -X- _ I-Outcome
molecular -X- _ I-Outcome
and -X- _ I-Outcome
immunological -X- _ I-Outcome
detection -X- _ I-Outcome
is -X- _ I-Outcome
necessary -X- _ I-Outcome
for -X- _ I-Outcome
surveillance -X- _ I-Outcome
and -X- _ I-Outcome
outbreak -X- _ I-Outcome
response. -X- _ I-Outcome
While -X- _ I-Outcome
pan-lineage -X- _ I-Outcome
ELISA -X- _ I-Outcome
and -X- _ I-Outcome
RDTs -X- _ I-Outcome
are -X- _ I-Outcome
commercially -X- _ I-Outcome
available -X- _ I-Outcome
( -X- _ I-Outcome
for -X- _ I-Outcome
research -X- _ I-Outcome
use -X- _ I-Outcome
only -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
validation -X- _ I-Outcome
and -X- _ I-Outcome
external -X- _ I-Outcome
quality -X- _ I-Outcome
assessment -X- _ I-Outcome
( -X- _ I-Outcome
EQA -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
needed -X- _ I-Outcome
to -X- _ I-Outcome
confirm -X- _ I-Outcome
detection -X- _ I-Outcome
sensitivity -X- _ I-Outcome
for -X- _ I-Outcome
all -X- _ I-Outcome
known -X- _ I-Outcome
or -X- _ I-Outcome
relevant -X- _ I-Outcome
strains. -X- _ I-Outcome
Variable -X- _ I-Outcome
sensitivity -X- _ I-Outcome
of -X- _ I-Outcome
LASV -X- _ I-Outcome
PCR -X- _ I-Outcome
tests -X- _ I-Outcome
also -X- _ I-Outcome
highlights -X- _ I-Outcome
the -X- _ I-Outcome
need -X- _ I-Outcome
for -X- _ I-Outcome
improved -X- _ I-Outcome
validation -X- _ I-Outcome
and -X- _ I-Outcome
EQA. -X- _ I-Outcome
Given -X- _ O
that -X- _ O
LASV -X- _ O
outbreaks -X- _ O
typically -X- _ O
occur -X- _ O
in -X- _ O
low-resource -X- _ O
settings -X- _ O
, -X- _ O
more -X- _ O
options -X- _ O
for -X- _ O
point-of-care -X- _ O
testing -X- _ O
would -X- _ O
be -X- _ O
valuable. -X- _ O
These -X- _ O
requirements -X- _ O
should -X- _ O
be -X- _ O
taken -X- _ O
into -X- _ O
account -X- _ O
in -X- _ O
target -X- _ O
product -X- _ O
profiles -X- _ O
for -X- _ O
improved -X- _ O
LASV -X- _ O
diagnostics -X- _ O
. -X- _ O

